Palliative chemotherapy with trofosfamide in advanced prostate cancer.

Abstract

BACKGROUND:

A phase II study with trofosfamide in hormone-refractory prostate cancer was conducted to test the palliative efficacy.

PATIENTS AND METHODS:

Twenty patients suffering from advanced prostate cancer were treated with per os trofosfamide after progression on androgen ablation and/or estramustine. The mean age was 72 years. The patients were treated with 150 mg/day as continuous treatment. The treatment was continued until progressive disease or severe toxicity.

RESULTS:

A decline in the prostate specific antigen (PSA) level was observed in 5 patients (27%) with a 0-25% decline in 2 patients and a >50% decline in 3 patients (16%, 95% confidence interval 3.4-39.6). There were no clinical or radiological complete (CR) or partial (PR) responses in 19 evaluable patients. Some toxicity was observed: 15 patients developed anaemia and grade 2-4 adverse effects were observed in 16 patients. One patient died of cardiac event.

CONCLUSION:

Trofosfamide has some activity in hormone-refractory advanced prostate cancer. When used in fragile or heavily pre-treated patients, careful monitoring for haematological and cardiac effects is recommended.

• Authors: E K Salminen, J Sundström, V Nikkanen
• Journal: Anticancer research (Anticancer Res) 2006 Jan-Feb Vol. 26 Issue 1B Pg. 539-42 ISSN: 0250-7005 [Print] Greece
• PMID: 16739316 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Cyclophosphamide
• Prostate-Specific Antigen
• trofosfamide

Topics

• Aged
• Aged, 80 and over
• Antineoplastic Agents, Alkylating (adverse effects, therapeutic use)
• Cyclophosphamide (adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Male
• Middle Aged
• Palliative Care
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (blood, drug therapy)